pharmorage

Targeting inflammation, enhancing mRNA vaccines.

Discover More
Tailoring the immune system through innovative therapies
About Us
Born in 2020 from a strategic alliance between Noxopharm Ltd and Hudson Institute of Medical Research (HIMR), Pharmorage aims at discovering and developing next generation anti-inflammatory drugs to treat diseases resulting from aberrant inflammation. To fulfil our mission, we leverage two proprietary innovative platforms based on small molecules and synthetic RNAs technologies.

Our Technologies

SMALL MOLECULES PLATFORM
(NOXOPHARM)
SYNTHETIC RNAs PLATFORM
(Hudson Institute of Medical Research)
INFECTION-DRIVEN INFLAMMATION AND SEPSIS
AUTO-IMMUNE DISEASES
mRNA THERAPEUTICS/VACCINES
Research
Pharmorage uses complementary technologies targeting two levels of the inflammatory signalling pathway. On one hand we are engineering new kinds of oligonucleotides to improve mRNA vaccines and treat a range of localised inflammatory diseases. On the other, our small molecule platform is exploring the treatment of systemic auto-immune disease and hyperinflammatory conditions.

Recent News